Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$29.93 - $35.06 $84,671 - $99,184
2,829 Added 416.64%
3,508 $118 Million
Q4 2023

Feb 14, 2024

BUY
$19.2 - $33.78 $13,036 - $22,936
679 New
679 $21.9 Million

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.1B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Point72 Asia (Singapore) Pte. Ltd. Portfolio

Follow Point72 Asia (Singapore) Pte. Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asia (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asia (Singapore) Pte. Ltd. with notifications on news.